DBDarren Bodkin

Darren Bodkin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Darren Bodkin has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Charles L. Cai

    Department of Pediatrics, State University of New York, Downstate Medical Center, Brooklyn, USA

    3 shared publications
  • Jacob V. Aranda

    Department of Pediatrics, State University of New York, Downstate Medical Center, Brooklyn, USA

    3 shared publications
  • Kay D. Beharry

    Department of Pediatrics, Division of Neonatal-Perinatal Medicine, State University of New York Downstate Health Sciences University, Brooklyn, NY 11203, USA

    3 shared publications
  • Ghassan Mustafa

    Department of Pediatrics, State University of New York, Downstate Medical Center, Brooklyn, USA

    2 shared publications
  • Abeer Azzuqa

    University of Pittsburgh Medical Center, Division of Newborn Medicine, Pittsburgh, USA

    1 shared publication
  • Alan P. Ladd

    Division of Pediatric Surgery, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, USA

    1 shared publication

Latest Publications

  • Open Access

    Case series of selenium insufficiency among infants with intestinal failure

    by Darren Bodkin, Alisha Hemani, Jessica Miller, Jennifer Fraysur, Erica Fuchs

  • Inter-center variations in length of hospitalization for infants with congenital jejunal or ileal atresia

    by Katie A. Huff, Isabella Zaniletti, Kera McNelis, Alan Ladd, Abeer Azzuqa, Carl H. Coghill, Daniel T. Robinson, Muralidhar H. Premkumar, Patricia W. Denning, Jae Kim, et al.

    Objective To quantify inter-center variation (ICV) in length of stay (LOS) among surviving infants with jejunal (JA) or ileal atresia (IA). Study design Children’s Hospitals Neonatal Consortium’s database was used to identify infants with JA or IA. After excluding infants with abdominal wall defects, survivors’ hospital LOS was modeled as a function of center using generalized linear models with log link for gamma distribution. Results There were 1134 and 808 infants with JA and IA, respectively. LOS had significant ICV in unadjusted (JA: 5.4 [IQR 3.7,9.9] weeks; IA: 4.3 [IQR 2.4,11.4] weeks) and multivariable analyses (JA: 4+ fold difference (6.5–31.5 week); p < 0.001 IA: 8+ fold difference (1.7–14.6 weeks); p < 0.001) with modifiable risk factors including cholestasis, ostomy creation, blood stream infection, and residual bowel length <55 cm. Conclusion Risk-adjusted ICV in LOS was observed in infants with JA and IA, which exposes opportunities for improvements in outcomes for infants with intestinal atresia.

  • Open Access

    Stability and heterogeneity in the antimicrobiota reactivity of human milk-derived immunoglobulin A

    by Chelseá B. Johnson-Hence, Kathyayini P. Gopalakrishna, Darren Bodkin, Kara E. Coffey, Ansen H.P. Burr, Syed Rahman, Ali T. Rai, Darryl A. Abbott, Yelissa A. Sosa, Justin T. Tometich, et al.

    Immunoglobulin A (IgA) is secreted into breast milk and is critical for both protecting against enteric pathogens and shaping the infant intestinal microbiota. The efficacy of breast milk–derived maternal IgA (BrmIgA) is dependent upon its specificity; however, heterogeneity in BrmIgA binding ability to the infant microbiota is not known. Using a flow cytometric array, we analyzed the reactivity of BrmIgA against bacteria common to the infant microbiota and discovered substantial heterogeneity between all donors, independent of preterm or term delivery. Surprisingly, we also observed intradonor variability in the BrmIgA response to closely related bacterial isolates. Conversely, longitudinal analysis showed that the antibacterial BrmIgA reactivity was relatively stable through time, even between sequential infants, indicating that mammary gland IgA responses are durable. Together, our study demonstrates that the antibacterial BrmIgA reactivity displays interindividual heterogeneity but intraindividual stability. These findings have important implications for how breast milk shapes the development of the preterm infant microbiota and protects against necrotizing enterocolitis.


  • Neonatal intermittent hypoxia, fish oil, and/or antioxidant supplementation on gut microbiota in neonatal rats

    by Darren Bodkin, Charles L. Cai, Alex Manlapaz-Mann, Ghassan Mustafa, Jacob V. Aranda, Kay D. Beharry

    Background Preterm infants frequently experience intermittent hypoxia (IH) episodes, rendering them susceptible to oxidative stress and gut dysbiosis. We tested the hypothesis that early supplementation with antioxidants and/or fish oil promotes gut biodiversity and mitigates IH-induced gut injury. Methods Newborn rats were exposed to neonatal IH from birth (P0) to P14 during which they received daily oral supplementation with: (1) coenzyme Q10 (CoQ10) in olive oil, (2) fish oil, (3) glutathione nanoparticles (nGSH), (4) CoQ10 + fish oil, or (5) olive oil (placebo control). Pups were placed in room air (RA) from P14 to P21 with no further treatment. RA controls were similarly treated. Stool samples were assessed for microbiota and terminal ileum for histopathology and morphometry, total antioxidant capacity, lipid peroxidation, and biomarkers of gut injury. Results Neonatal IH induced histopathologic changes consistent with necrotizing enterocolitis, which were associated with increased lipid peroxidation, toll-like receptor, transforming growth factor, and nuclear factor kappa B. Combination of CoQ10 + fish oil and nGSH were most effective for preserving gut integrity, reducing biomarkers of gut injury, and increasing commensal organisms. Conclusions Combination of antioxidants and fish oil may confer synergistic benefits to mitigate IH-induced injury in the terminal ileum. Impact Antioxidant and fish oil (PUFA) co-treatment was most beneficial for reducing neonatal IH-induced gut injury. The synergistic effects of antioxidant and fish oil is likely due to prevention of IH-induced ROS attack on lipids, thus preserving and augmenting its therapeutic benefits. Combination treatment was also effective for increasing the abundance of the non-pathogenic Firmicutes phylum, which is associated with a healthy gastrointestinal system of the newborn. Extremely low gestational age neonates who are at high risk for frequent, repetitive neonatal IH and oxidative stress-induced diseases may benefit from this combination therapy.


  • Effects of omega 3 polyunsaturated fatty acids, antioxidants, and/or non‐steroidal inflammatory drugs in the brain of neonatal rats exposed to intermittent hypoxia

    by Alex Manlapaz‐Mann, Charles L. Cai, Darren Bodkin, Ghassan Mustafa, Jacob V. Aranda, Kay D. Beharry

    Preterm infants experience frequent arterial oxygen desaturations during oxygen therapy, or intermittent hypoxia (IH). Neonatal IH increases oxidative distress which contributes to neuroinflammation and brain injury. We tested the hypotheses that exposure to neonatal IH is detrimental to the immature brain, and that early supplementation with antioxidants and/or omega 3 polyunsaturated fatty acids (n‐3 PUFAs) combined with non‐steroidal anti‐inflammatory drugs (NSAIDs) is protective. Newborn rats were exposed to brief hypoxia (12% O2) during hyperoxia (50% O2) from the first day of life (P0) until P14 during which they received daily oral supplementation with antioxidants, namely coenzyme Q10 (CoQ10) or glutathione nanoparticles (nGSH), n‐3 PUFAs and/or topical ocular ketorolac. Placebo controls received daily oral olive oil and topical ocular saline. Room air (RA) littermates remained in 21% O2 from birth to P21 with all treatments identical. At P14 animals were allowed to recover in RA until P21 with no further treatment. Whole brains were harvested for histopathology and morphometric analyses, and assessed for biomarkers of oxidative stress and inflammation, as well as myelin injury. Neonatal IH resulted in higher brain/body weight ratios, an effect that was reversed with n‐3 PUFAs and n‐3 PUFAs+CoQ10 with or without ketorolac. Neonatal IH was also associated with hemorrhage, oxidative stress and elevations in inflammatory prostanoids. Supplementation with n‐3 PUFAs and nGSH with and without ketorolac were most beneficial for myelin growth and integrity when administered in RA. However, the benefit of n‐3 PUFAs was significantly curtailed in neonatal IH. Neonatal IH during a critical time of brain development causes inflammation and oxidative injury. Loss of therapeutic benefits of n‐3 PUFAs suggest its susceptibility to oxidation in neonatal IH and therefore indicate that co‐administration with antioxidants may be necessary to sustain its efficacy.